Biogen (BIIB) Tops Q3 EPS by 68c; Announces Corp. Restructuring; Boosts FY15 EPS Outlook

Leerink Partners Remains Bullish on Biogen (BIIB) Following 3Q Earnings Results

October 21, 2015 1:42 PM EDT

Leerink Partners reiterated an Outperform rating and $425.00 price target on Biogen (NASDAQ: BIIB) following the company's 3Q15 earnings results. BIIB reported a 3Q beat on all top and bottom line levels. 3Q sales of 2.78 bn. vs. consensus estimates of $2.6B, 3Q non-GAAP EPS of 4.48 vs.... More

Cowen Remains Bullish as Biogen (BIIB) Reports 3Q EPS Beat

October 21, 2015 1:36 PM EDT

Cowen reiterated an Outperform rating and $368.00 price target on Biogen (NASDAQ: BIIB) following the company's 3Q15 earnings results. BIIB reported strong Q3 non-GAAP EPS of $4.48 vs. consensus of $3.84E, on revenue of $2.8B.

Analyst Eric Schmidt commented, "BIIB reported Q3 revenue and earnings well above... More

RBC Comments on Bull/Bear Case on Biogen (BIIB) Following Q3 Results

October 21, 2015 9:22 AM EDT

RBC Capital maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $450. Earlier Biogen reported Q3 results including a corporate restructuring and headcount reduction. In the view of analyst Michael J. Yee, this was relative good news against very low... More

Biogen to cut 11 percent of staff, cancel some drug programs; stock jumps

October 21, 2015 7:45 AM EDT

By Bill Berkrot

(Reuters) - Biogen Inc (NASDAQ: BIIB), whose shares have tumbled since it slashed growth forecasts for its top-selling multiple sclerosis drug in July, said it will cut 11 percent of its workforce and eliminate development of several drugs to focus on high-priority medicines in its pipeline.

Wall Street signaled its approval of the belt-tightening as well as better-than-expected third-quarter sales of Biogen's multiple sclerosis drugs, sending its shares up as much as 9.5 percent. But most of the gains evaporated by midday.

The restructuring, announced on Wednesday, will reduce operating... More

Biogen (BIIB) will resume trading at 8:00am ET

October 21, 2015 7:40 AM EDT

Biogen (NASDAQ: BIIB) will resume trading at 8:00am EDT.

... More

Biogen's (BIIB) Phase 3 ASCEND Trial Missed Primary, Secondary Endpoints

October 21, 2015 7:32 AM EDT

The Phase 3 ASCEND study investigating natalizumab in the treatment of secondary progressive multiple sclerosis (SPMS) did not achieve its primary and secondary endpoints, Biogen (NASDAQ: BIIB) reported today. During the study, natalizumab was generally well tolerated and adverse events were consistent with its known safety profile.

ASCEND evaluated the efficacy and... More

Biogen (BIIB) Halted, News Pending

October 21, 2015 7:25 AM EDT

Biogen (NASDAQ: BIIB) Halted, News Pending

... More